RM Global Closes Biopharma Investment Fund, at US$64M

life sciencesRM Global, an Israel-based investment banking, fund management, and strategic advisory firm, announced the closing of its biopharma investment fund, at US$64M.

The additional capital, coming from institutional, family office and strategic life science investors from South Korea, the U.S., Europe and Israel, will continue to support the development of innovative Best-in-Class/First-in-Class biotherapeutics in areas including:
– Oncology,
– CNS,
– Orphan Diseases, and
– others.

The RMGP Biopharma Investment Fund started operations following the initial closing in May 2017. To date, its portfolio consists of 11 companies, representing investments in both seed and follow-on rounds, including the recent BiomX Series B financing.

Managed by RM Global (RMG), the fund focuses on investing in innovative life science technologies with a global perspective. The firm’s portfolio focuses on biotherapeutics developed within the Israel-based FutuRx incubator, established by OrbiMed Israel, Johnson & Johnson Innovation, and Takeda Ventures – in cooperation with the Israel Innovation Authority (IIA).



Join the discussion